Medical Doctor Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Amal Elhaj

Neurology Belmont, NC Medical Doctor

NPI 1144647041 CMS profile 8500914

1212 Spruce St, Belmont, NC 28012

Open in the dashboard

General payments

$3,899

253 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Amal Elhaj of Belmont, NC is reported in the CMS Open Payments database as having received $3,899 across 253 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $14 1
2023 General $509 29
2022 General $1,572 99
2021 General $1,509 105
2020 General $295 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amal Elhaj
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Amal Elhaj were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Amal Elhaj Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $295 $367 $82–$2,309 $114
2021 $1,509 $438 $104–$2,547 $132
2022 $1,572 $442 $103–$2,388 $149
2023 $509 $464 $119–$2,312 $160
2024 $14 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. Novartis Pharmaceuticals Corporation $552 53 payments
  2. AbbVie, Inc. $339 27 payments
  3. EMD Serono, Inc. $250 15 payments
  4. Teva Pharmaceuticals USA, Inc. $246 18 payments
  5. UCB, Inc. $244 13 payments
  6. Biogen, Inc. $175 10 payments
  7. Genentech USA, Inc. $174 9 payments
  8. Eisai Inc. $167 9 payments
  9. SK Life Science, Inc. $166 9 payments
  10. Aquestive Therapeutics, Inc. $123 6 payments
  11. Other $1,464 84 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Food and Beverage $3,878 252 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22 1 payment
Products named General payments · program years 2020–2024
  1. KESIMPTA $326 34 payments
  2. AIMOVIG $259 21 payments
  3. OCREVUS $174 9 payments
  4. Dayvigo $149 8 payments
  5. NURTEC ODT $146 9 payments
  6. UBRELVY $142 11 payments
  7. AJOVY $134 9 payments
  8. SYMPAZAN $123 6 payments
  9. QULIPTA $118 9 payments
  10. AUSTEDO $113 9 payments
  11. Other $2,094 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,004

Median for Neurology: 833

Drug cost

$109,412

Median for Neurology: $202,670

Branded share of claims

13.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aptiom Eslicarbazepine Acetate Brand 16 $41,269
Briviact Brivaracetam Brand 18 $37,992
Lacosamide Generic 43 $11,870
Levetiracetam Generic 145 $4,196
Memantine Hcl Generic 125 $2,916
Levetiracetam Er Levetiracetam Brand 50 $2,708
Pregabalin Generic 43 $1,030
Donepezil Hcl Generic 106 $986
Lamotrigine Generic 48 $916
Gabapentin Generic 69 $806

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$15,107

Medicare's payments for the services billed

Medicare patients

85

Average age 72

Services billed

135

50 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 41%
Arthritis 40%
Depression 34%
Ischemic heart disease 32%
Chronic kidney disease 29%
Atrial fibrillation 22%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

253 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record